Swiss National Bank increased its stake in Glaukos Corp. (NYSE:GKOS) by 37.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,300 shares of the company’s stock after buying an additional 5,800 shares during the period. Swiss National Bank owned approximately 0.07% of Glaukos Corp. worth $621,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Inspirion Wealth Advisors LLC bought a new stake in shares of Glaukos Corp. during the second quarter valued at about $289,000. Spark Investment Management LLC bought a new stake in shares of Glaukos Corp. during the first quarter valued at about $300,000. Strs Ohio increased its stake in shares of Glaukos Corp. by 409.1% in the second quarter. Strs Ohio now owns 11,200 shares of the company’s stock valued at $326,000 after buying an additional 9,000 shares in the last quarter. BP PLC bought a new stake in shares of Glaukos Corp. during the second quarter valued at about $426,000. Finally, Essex Investment Management Co. LLC bought a new stake in shares of Glaukos Corp. during the second quarter valued at about $614,000. 71.91% of the stock is owned by institutional investors.
Shares of Glaukos Corp. (NYSE:GKOS) traded down 0.78% during mid-day trading on Thursday, reaching $35.50. 282,957 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $35.07 and its 200 day moving average price is $28.34. The company’s market cap is $1.17 billion. Glaukos Corp. has a 52-week low of $14.25 and a 52-week high of $39.82.
Glaukos Corp. (NYSE:GKOS) last issued its quarterly earnings results on Monday, August 1st. The company reported $0.06 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.10. The firm had revenue of $28.60 million for the quarter, compared to the consensus estimate of $24.45 million. Glaukos Corp. had a negative net margin of 1.23% and a negative return on equity of 1.14%. The company’s revenue for the quarter was up 60.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.30) EPS. On average, equities research analysts predict that Glaukos Corp. will post $0.11 EPS for the current year.
A number of research analysts recently weighed in on the stock. Stifel Nicolaus reaffirmed a “hold” rating on shares of Glaukos Corp. in a research report on Tuesday, September 27th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $41.00 target price on shares of Glaukos Corp. in a research report on Sunday, September 25th. Zacks Investment Research raised shares of Glaukos Corp. from a “hold” rating to a “strong-buy” rating and set a $44.00 target price for the company in a research report on Wednesday, October 5th. Roth Capital raised their target price on shares of Glaukos Corp. from $36.50 to $41.00 and gave the company a “buy” rating in a research report on Tuesday, August 2nd. Finally, Piper Jaffray Cos. raised their target price on shares of Glaukos Corp. to $42.00 in a research report on Tuesday, August 2nd. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Glaukos Corp. has an average rating of “Buy” and an average price target of $39.20.
In related news, CFO Richard L. Harrison sold 10,000 shares of the business’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $35.01, for a total transaction of $350,100.00. Following the transaction, the chief financial officer now owns 11,388 shares in the company, valued at approximately $398,693.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Orbimed Advisors Llc sold 425,000 shares of the business’s stock in a transaction on Wednesday, August 3rd. The shares were sold at an average price of $30.59, for a total transaction of $13,000,750.00. The disclosure for this sale can be found here. 36.80% of the stock is currently owned by insiders.
About Glaukos Corp.
Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide.
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp. (NYSE:GKOS).
Receive News & Ratings for Glaukos Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corp. and related companies with MarketBeat.com's FREE daily email newsletter.